Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Cara Therapeutics stock

CARA
US1407551092
A1XDTK

Price

0.26
Today +/-
-0.01
Today %
-2.19 %

Cara Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Cara Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Cara Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Cara Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Cara Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Cara Therapeutics Stock Price History

DateCara Therapeutics Price
12/6/20240.26 undefined
12/6/20240.27 undefined
12/5/20240.27 undefined
12/4/20240.27 undefined
12/3/20240.28 undefined
12/2/20240.29 undefined
11/29/20240.30 undefined
11/27/20240.29 undefined
11/26/20240.29 undefined
11/25/20240.30 undefined
11/22/20240.31 undefined
11/21/20240.31 undefined
11/20/20240.31 undefined
11/19/20240.30 undefined
11/18/20240.29 undefined
11/15/20240.31 undefined
11/14/20240.33 undefined
11/13/20240.33 undefined
11/12/20240.34 undefined
11/11/20240.34 undefined
11/8/20240.34 undefined

Cara Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cara Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cara Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cara Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cara Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cara Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cara Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cara Therapeutics’s growth potential.

Cara Therapeutics Revenue, EBIT and net profit per share

DateCara Therapeutics RevenueCara Therapeutics EBITCara Therapeutics Net Income
2029e122.58 M undefined11.28 M undefined-10.45 M undefined
2028e65.5 M undefined-30.48 M undefined-35.07 M undefined
2027e19.79 M undefined-56.98 M undefined-45.7 M undefined
2026e7.42 M undefined-46.78 M undefined-35.44 M undefined
2025e6.55 M undefined-53.06 M undefined-43.09 M undefined
2024e6.76 M undefined-73.57 M undefined-71.81 M undefined
202320.97 M undefined-121.5 M undefined-118.51 M undefined
202241.9 M undefined-87.5 M undefined-85.5 M undefined
202123 M undefined-89.1 M undefined-88.4 M undefined
2020135.1 M undefined5.4 M undefined8.4 M undefined
201919.9 M undefined-111.7 M undefined-106.4 M undefined
201813.5 M undefined-77.4 M undefined-74 M undefined
2017900,000 undefined-59.5 M undefined-58.1 M undefined
2016100,000 undefined-58.4 M undefined-57.3 M undefined
20153.8 M undefined-25.2 M undefined-24.7 M undefined
20143.2 M undefined-18.1 M undefined-17.7 M undefined
201312 M undefined-200,000 undefined-3.1 M undefined
20121.2 M undefined-6.2 M undefined-6.3 M undefined
20110 undefined-9.6 M undefined-9.8 M undefined

Cara Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0112330013191352341206671965122
--1,100.00-75.00----46.15610.53-82.9678.26-51.22-70.00-16.67171.43242.1187.69
-1,400.00116.67466.67466.67--107.6973.6810.3760.8782.9370.00233.33233.33200.0073.6821.5411.48
000000000003414000000
-9-6-3-17-24-57-58-74-1068-88-85-118-71-43-35-45-35-10
--33.33-50.00466.6741.18137.501.7527.5943.24-107.55-1,200.00-3.4138.82-39.83-39.44-18.6028.57-22.22-71.43
4.121.84.12124.627.331.235.942.747.950.753.754.15000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Cara Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cara Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
4.11.112.452.7106.758.392.6161.4155180.9167145.4100.76
000000000003.32.77
000000000001.21.25
00000000002.62.42.82
0.40.12.10.31.72.21.65.28.912.12.516.78.56
4.51.214.553108.460.594.2166.6163.9193172.1169116.16
5.43.62.82.11.31.61.20.93.75.13.628.19
000000021.463.270.669.811.40
0000000000000
0000000000000
0000000000000
0.70.70.70.70.70.80.80.40.40.40.401.5
6.14.33.52.822.4222.767.376.173.813.49.69
10.65.51855.8110.462.996.2189.3231.2269.1245.9182.4125.84
                         
58.258.565.60000000.10.10.10.05
11.28.4131.8209.9212.9307.2428.1587.2641.2708.6726.6742.04
-53.1-59.4-62.5-80.2-104.9-162.2-220.3-294.4-400.7-392.3-480.8-566.2-684.75
02.10000-0.1-0.10.20.1-0.4-1.7-0.26
0000000000000
6.12.411.551.610550.786.8133.6186.7249.1227.5158.857.08
0.70.50.70.524.73.84.49.14.95.69.611.58
1.50.41.31.43.36.84.79.311.513.61213.914.01
003.51.500026.822.30000
050000000000000
80030000000000000
31.75.53.45.311.58.540.542.918.517.623.525.59
1.6000000000000
0000000000000
0.11.41.10.90.61.61.716.73.43.71.9043.17
1.71.41.10.90.61.61.716.73.43.71.9043.17
4.73.16.64.35.913.110.257.246.322.219.523.568.76
10.85.518.155.9110.963.897190.8233271.3247182.3125.84
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cara Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cara Therapeutics's financial health and stability.

Assets

Cara Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cara Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cara Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cara Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-9-6-3-17-24-57-58-74-1068-88-85-118
1,0001,0000001,0000000000
0000000000000
10-1015-310-75-129
007035115988433716
0000000000000
0000000000000
-6-62-17-21-47-54-22-109-5-60-78-92
000000000000-2
0000-9145-36-82-30-20-412843
0000-9145-36-82-30-19-412845
0000000000000
0200000000000
9075775087110142394601
92857750871101423946038
00000000000036
0000000000000
2-21140-37-2-35213-1850-10
-6.87-6.032.82-17.68-21.5-48.1-54.89-22.37-109.25-5.84-60.13-78.77-94.45
0000000000000

Cara Therapeutics stock margins

The Cara Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cara Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cara Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cara Therapeutics's sales revenue. A higher gross margin percentage indicates that the Cara Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cara Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cara Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cara Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cara Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cara Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cara Therapeutics Margin History

Cara Therapeutics Gross marginCara Therapeutics Profit marginCara Therapeutics EBIT marginCara Therapeutics Profit margin
2029e70.56 %9.2 %-8.52 %
2028e70.56 %-46.54 %-53.54 %
2027e70.56 %-287.92 %-230.94 %
2026e70.56 %-630.75 %-477.88 %
2025e70.56 %-809.61 %-657.42 %
2024e70.56 %-1,088.8 %-1,062.77 %
202370.56 %-579.43 %-565.21 %
202282.58 %-208.83 %-204.06 %
202170.56 %-387.39 %-384.35 %
202070.56 %4 %6.22 %
201970.56 %-561.31 %-534.67 %
201870.56 %-573.33 %-548.15 %
201770.56 %-6,611.11 %-6,455.56 %
2016-800 %-58,400 %-57,300 %
201570.56 %-663.16 %-650 %
201470.56 %-565.63 %-553.13 %
201370.56 %-1.67 %-25.83 %
201270.56 %-516.67 %-525 %
201170.56 %0 %0 %

Cara Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Cara Therapeutics earnings per share therefore indicates how much revenue Cara Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cara Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cara Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cara Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cara Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cara Therapeutics Revenue, EBIT and net profit per share

DateCara Therapeutics Sales per ShareCara Therapeutics EBIT per shareCara Therapeutics Earnings per Share
2029e2.23 undefined0 undefined-0.19 undefined
2028e1.19 undefined0 undefined-0.64 undefined
2027e0.36 undefined0 undefined-0.83 undefined
2026e0.14 undefined0 undefined-0.65 undefined
2025e0.12 undefined0 undefined-0.79 undefined
2024e0.12 undefined0 undefined-1.31 undefined
20230.39 undefined-2.24 undefined-2.19 undefined
20220.78 undefined-1.63 undefined-1.59 undefined
20210.45 undefined-1.76 undefined-1.74 undefined
20202.82 undefined0.11 undefined0.18 undefined
20190.47 undefined-2.62 undefined-2.49 undefined
20180.38 undefined-2.16 undefined-2.06 undefined
20170.03 undefined-1.91 undefined-1.86 undefined
20160 undefined-2.14 undefined-2.1 undefined
20150.15 undefined-1.02 undefined-1 undefined
20140.15 undefined-0.86 undefined-0.84 undefined
20132.93 undefined-0.05 undefined-0.76 undefined
20120.06 undefined-0.28 undefined-0.29 undefined
20110 undefined-2.34 undefined-2.39 undefined

Cara Therapeutics business model

Cara Therapeutics Inc. is a US pharmaceutical company based in Stamford, Connecticut, specializing in the development of novel therapies for the treatment of pain conditions. The company was founded in 2004 by Derek Chalmers and Eric Carter and has been publicly traded on the NASDAQ since its IPO in 2014. Cara Therapeutics Inc.'s history is closely linked to the discovery of adenosine A2A receptor modulation. In recent years, the company has successfully utilized this class of compounds in innovative ways to develop novel pain treatment solutions. The company also has a close collaboration with Yale University and other leading research institutions in the field of neurology and pain research. Cara Therapeutics Inc.'s business model is based on the development and commercialization of new pain therapies, particularly based on Cara - a synthetic adenosine A2A receptor antagonist. The medications developed by Cara Therapeutics Inc. are designed to provide effective pain relief to patients without the strong side effects of traditional pain medications such as opioids. Cara Therapeutics Inc. is divided into several divisions that encompass different areas of the company. These include research and development, production, sales and marketing, as well as the supply chain. The research and development division of Cara Therapeutics Inc. works closely with leading research institutions and scientists to continuously develop new treatment options. The focus is always on the needs of patients and healthcare providers, with an emphasis on advancing treatment options with Cara and other new compounds. The production facilities of Cara Therapeutics Inc. are specialized in the production of Cara-based therapies and aim to ensure high quality and patient access. The company works closely with various partners domestically and internationally to ensure global patient access. The sales and marketing division of Cara Therapeutics Inc. is focused on placing the company's products on the market and communicating the benefits of the offered therapies to patients. The company relies on a global network of distribution partners and close collaboration with healthcare professionals. An important focus of the company is the supply chain - ensuring continuous patient access to necessary medications as well as ensuring compatibility and traceability of treatment options. Some of the most well-known and important products of Cara Therapeutics Inc. include Korsuva, a pain medication developed for the treatment of pruritus in patients with chronic kidney disease on hemodialysis, as well as a wide range of other pain therapies. Overall, Cara Therapeutics Inc. is an innovative company specializing in the treatment of pain conditions and is at the forefront of pain therapy research and development. The company places special emphasis on ensuring that their pain therapies are as effective and safe as possible in order to provide patients with effective pain relief. Cara Therapeutics is one of the most popular companies on Eulerpool.com.

Cara Therapeutics SWOT Analysis

Strengths

Cara Therapeutics Inc has a strong pipeline of innovative pharmaceutical products, with a focus on developing novel therapeutics for the treatment of pain and pruritus.

The company has a dedicated and experienced research and development team, which enables them to continuously advance their drug candidates and explore new opportunities in the healthcare market.

Weaknesses

Cara Therapeutics Inc heavily relies on the success of its drug candidates, and any setbacks in clinical trials or regulatory approvals could have a significant negative impact on the company's financial performance.

The company may face challenges in effectively commercializing and marketing their products, as the pharmaceutical industry is highly competitive and getting drugs effectively to market requires strong marketing and distribution capabilities.

Opportunities

The global pharmaceutical market is expected to grow in the coming years, presenting opportunities for Cara Therapeutics Inc to expand its product portfolio and enter new markets.

Increasing awareness and demand for pain management and pruritus treatment options provide the company with a favorable market environment to launch its innovative drugs.

Threats

The pharmaceutical industry is highly regulated, and any changes in regulations, pricing policies, or reimbursement systems could pose challenges for Cara Therapeutics Inc in terms of market access and profitability.

The company faces competition from large pharmaceutical companies and other biotechnology firms, which may have greater resources and established market presence, making it difficult for Cara Therapeutics Inc to gain a significant market share.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cara Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Cara Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cara Therapeutics shares outstanding

The number of shares was Cara Therapeutics in 2023 — This indicates how many shares 54.149 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cara Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cara Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cara Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cara Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Cara Therapeutics.

Cara Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.25 -0.23  (8.59 %)2024 Q3
6/30/2024-0.28 -0.37  (-32.38 %)2024 Q2
3/31/2024-0.41 -0.56  (-37.93 %)2024 Q1
12/31/2023-0.42 -0.59  (-40.41 %)2023 Q4
9/30/2023-0.53 -0.52  (1.96 %)2023 Q3
6/30/2023-0.55 -0.58  (-5.63 %)2023 Q2
3/31/2023-0.53 -0.49  (7.88 %)2023 Q1
12/31/2022-0.33 -0.56  (-71.57 %)2022 Q4
9/30/2022-0.43 -0.43  (-0.73 %)2022 Q3
6/30/2022-0.26 -0.08  (69.04 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Cara Therapeutics stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

19

👫 Social

57

🏛️ Governance

25

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees58
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cara Therapeutics shareholders

%
Name
Stocks
Change
Date
13.48299 % Vifor (International), Ltd7,396,77007/25/2023
4.10196 % The Vanguard Group, Inc.2,250,334-230,9246/30/2024
3.52847 % Disciplined Growth Investors, Inc.1,935,718120,6606/30/2024
3.10264 % Chescapmanager, L.L.C.1,702,11006/30/2024
2.83677 % Farallon Capital Management, L.L.C.1,556,25106/30/2024
2.03385 % Two Sigma Investments, LP1,115,769166,9116/30/2024
1.96283 % BNP Paribas Securities Corp. North America1,076,807790,6026/30/2024
1.94267 % Renaissance Technologies LLC1,065,750-266,7286/30/2024
1.30959 % BlackRock Institutional Trust Company, N.A.718,439-2,344,0206/30/2024
1.06955 % Millennium Management LLC586,755-75,0796/30/2024
1
2
3
4
5
...
10

Cara Therapeutics Executives and Management Board

Mr. Christopher Posner

(53)
Cara Therapeutics President, Chief Executive Officer, Director (since 2018)
Compensation 2.51 M

Mr. Ryan Maynard

(53)
Cara Therapeutics Chief Financial Officer
Compensation 1.89 M

Dr. Frederique Menzaghi

(56)
Cara Therapeutics Senior Vice President - Research and Development, Chief Scientific Officer (since 2019)
Compensation 1.74 M

Mr. Scott Terrillion

(60)
Cara Therapeutics Chief Compliance Officer, General Counsel, Secretary
Compensation 1.59 M

Dr. Joana Goncalves

(49)
Cara Therapeutics Chief Medical Officer
Compensation 1.55 M
1
2
3

Most common questions regarding Cara Therapeutics

What values and corporate philosophy does Cara Therapeutics represent?

Cara Therapeutics Inc represents a commitment to advancing innovative pharmaceutical solutions. The company's values include dedication to scientific excellence, patient-centric approaches, and improving the quality of patient lives. With a focus on developing novel therapies to address unmet medical needs, Cara Therapeutics Inc aims to make a positive impact in the healthcare industry. By utilizing cutting-edge research and development, the company strives to deliver effective treatments for conditions such as chronic kidney disease-associated pruritus and acute post-operative pain. Embracing a culture of collaboration, Cara Therapeutics Inc emphasizes teamwork, integrity, and forward-thinking to drive progress in the field of biopharmaceuticals.

In which countries and regions is Cara Therapeutics primarily present?

Cara Therapeutics Inc is primarily present and operates in the United States.

What significant milestones has the company Cara Therapeutics achieved?

Cara Therapeutics Inc has achieved significant milestones in its journey. The company successfully developed and advanced its lead product candidate, Korsuva™ injection, for the treatment of chronic kidney disease-associated pruritus (CKD-aP). They have collaborated with Vifor Pharma Group to commercialize Korsuva™ injection globally, excluding the US, Japan, and South Korea. Additionally, Cara Therapeutics has conducted successful clinical trials, meeting primary and secondary endpoints, further validating the efficacy and safety of their products. The company's achievements demonstrate their commitment to addressing unmet medical needs and improving patients' quality of life.

What is the history and background of the company Cara Therapeutics?

Cara Therapeutics Inc is a pharmaceutical company focusing on developing and commercializing new medicines to alleviate pain and pruritus. Founded in 2004, the company is headquartered in Stamford, Connecticut. With a primary focus on targeting kappa opioid receptors, Cara Therapeutics aims to provide novel treatments for a range of medical conditions. The company has a diverse pipeline of potential therapies, including its lead product candidate, KORSUVA™ injection, which is being evaluated for the treatment of moderate-to-severe chronic kidney disease-associated pruritus. Cara Therapeutics Inc continues to drive innovation and strives to improve the lives of patients worldwide through its cutting-edge research and development efforts.

Who are the main competitors of Cara Therapeutics in the market?

Cara Therapeutics Inc faces competition from prominent companies in the market. Some of its main competitors include [insert competitor names here]. These companies operate in the same industry as Cara Therapeutics Inc and offer similar products or services. However, Cara Therapeutics Inc has carved out a niche for itself with its unique approaches and innovative solutions. Despite the competitive landscape, Cara Therapeutics Inc continues to strive towards success and deliver value to its shareholders and customers.

In which industries is Cara Therapeutics primarily active?

Cara Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Cara Therapeutics?

Cara Therapeutics Inc.'s business model revolves around the development and commercialization of innovative pharmaceutical products to alleviate pain and pruritus. With a focus on targeting selective receptors in the body, Cara Therapeutics aims to provide safer and more effective solutions for individuals suffering from pain and itching disorders. By leveraging its expertise in cannabinoid receptors and kappa opioid receptor modulation, the company strives to bring novel therapies to patients in need. Through its research, development, and commercialization efforts, Cara Therapeutics Inc. aims to improve patient outcomes and enhance their quality of life.

What is the P/E ratio of Cara Therapeutics 2024?

The Cara Therapeutics P/E ratio is -0.2.

What is the P/S ratio of Cara Therapeutics 2024?

The Cara Therapeutics P/S ratio is 2.09.

What is the Quality Investing of Cara Therapeutics?

The Quality Investing for Cara Therapeutics is 3/10.

What is the revenue of Cara Therapeutics 2024?

The expected Cara Therapeutics revenue is 6.76 M USD.

How high is the profit of Cara Therapeutics 2024?

The expected Cara Therapeutics profit is -71.81 M USD.

What is the business model of Cara Therapeutics

Cara Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of products to improve pain treatment. The company utilizes innovative technologies to identify molecules that inhibit pain signals in the body and thus improve pain therapy. Cara Therapeutics is listed on the NASDAQ and is headquartered in Stamford, Connecticut, USA. Cara Therapeutics' business model includes three main divisions. The first division is research and development of new pain therapies. The company uses cutting-edge technologies and a deep understanding of the biology of pain to develop drugs that can improve pain treatment. The company is committed to finding a better pain therapy that is safer and more effective than conventional medications. The second division focuses on the commercialization of already developed drugs. The company's main product, Korsuva®, is already being successfully marketed. Korsuva® is an oral medication for the treatment of chronic pruritus in patients with itching. The drug is currently in phase III of clinical trials and is expected to be launched in the near future. Cara Therapeutics has exclusive rights to market Korsuva® in the US, and there is strong evidence that it could be a very promising candidate. The third division is dedicated to collaboration and partnership with other biopharmaceutical companies and industry leaders. This is intended to accelerate the development and commercialization of products by leveraging the partners' expertise and know-how. For example, Cara Therapeutics is working with Vifor Pharma to market Korsuva® in Europe and other countries worldwide. In addition to Korsuva®, Cara Therapeutics is working on other products for pain treatment. The drug CR845 for the treatment of acute postoperative pain and acute pain is currently in phase III of clinical trials. Cara Therapeutics is a company with a clear and promising business model. The research and development of new pain therapies, the commercialization of Korsuva®, and collaboration with other biopharma companies will undoubtedly drive the company's progress. It remains to be seen how well Korsuva® and the company's other products will fare in the market, but the current stages of development and collaborations with industry leaders suggest that Cara Therapeutics is on the right track. The answer is: Cara Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of pain treatment products. The company uses innovative technologies to identify molecules that inhibit pain signals in the body and improve pain therapy. It is listed on the NASDAQ and based in Stamford, Connecticut, USA. Its business model includes research and development of new pain therapies, marketing already developed drugs like Korsuva®, and collaboration with other biopharma companies. It also has exclusive rights to market Korsuva® in the USA and is working on other pain treatment products. Overall, Cara Therapeutics has a promising business model and is positioned for further success.

What is the Cara Therapeutics dividend?

Cara Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Cara Therapeutics pay dividends?

The dividend cannot currently be calculated for Cara Therapeutics or the company does not pay out a dividend.

What is the Cara Therapeutics ISIN?

The ISIN of Cara Therapeutics is US1407551092.

What is the Cara Therapeutics WKN?

The WKN of Cara Therapeutics is A1XDTK.

What is the Cara Therapeutics ticker?

The ticker of Cara Therapeutics is CARA.

How much dividend does Cara Therapeutics pay?

Over the past 12 months, Cara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cara Therapeutics?

The current dividend yield of Cara Therapeutics is .

When does Cara Therapeutics pay dividends?

Cara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cara Therapeutics?

Cara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cara Therapeutics located?

Cara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cara Therapeutics from 12/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/7/2024.

When did Cara Therapeutics pay the last dividend?

The last dividend was paid out on 12/7/2024.

What was the dividend of Cara Therapeutics in the year 2023?

In the year 2023, Cara Therapeutics distributed 0 USD as dividends.

In which currency does Cara Therapeutics pay out the dividend?

The dividends of Cara Therapeutics are distributed in USD.

All fundamentals about Cara Therapeutics

Our stock analysis for Cara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.